Should I buy or sell Chemomab Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chemomab Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CMMB shares. View CMMB analyst ratings or view top-rated stocks .

What is Chemomab Therapeutics' stock price target for 2024?

3 analysts have issued 1-year price targets for Chemomab Therapeutics' stock. Their CMMB share price targets range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 929.4% from the stock's current price. View analysts price targets for CMMB or view top-rated stocks among Wall Street analysts .

How have CMMB shares performed in 2024?

Chemomab Therapeutics' stock was trading at $0.51 at the start of the year. Since then, CMMB stock has increased by 33.3% and is now trading at $0.68. View the best growth stocks for 2024 here .

Are investors shorting Chemomab Therapeutics?

Chemomab Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 221,900 shares, an increase of 14.3% from the March 15th total of 194,200 shares. Based on an average trading volume of 224,000 shares, the short-interest ratio is presently 1.0 days. Currently, 1.9% of the shares of the stock are sold short. View Chemomab Therapeutics' Short Interest .

When is Chemomab Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CMMB earnings forecast .

How were Chemomab Therapeutics' earnings last quarter?

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) announced its quarterly earnings results on Thursday, March, 7th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.14. During the same period last year, the firm posted ($0.72) earnings per share.

How do I buy shares of Chemomab Therapeutics?

Shares of CMMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CMMB

Chemomab Therapeutics (CMMB) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free CMMB Stock Alerts

$0.68

-0.02 (-2.86%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.66
▼
$0.74
50-Day Range: $0.59
▼
$0.86
52-Week Range: $0.42
▼
$1.89

Volume: 15,392 shs
Average Volume: 200,306 shs
Market Capitalization: $7.51 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Get Chemomab Therapeutics alerts:

Chemomab Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 929.4% Upside
$7.00 Price Target
Short Interest: Healthy
1.87% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.20) to ($1.50) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.45 out of 5 stars

3.3

Analyst's Opinion

Consensus Rating
Chemomab Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Chemomab Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.87% of the float of Chemomab Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Chemomab Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Chemomab Therapeutics has recently increased by 14.26%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Chemomab Therapeutics does not currently pay a dividend.
Dividend Growth
Chemomab Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CMMB.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Chemomab Therapeutics this week, compared to 1 article on an average week.
Search Interest
4 people have searched for CMMB on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Chemomab Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.91% of the stock of Chemomab Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
46.05% of the stock of Chemomab Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Chemomab Therapeutics are expected to decrease in the coming year, from ($1.20) to ($1.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Chemomab Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Chemomab Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Chemomab Therapeutics has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Chemomab Therapeutics Stock (NASDAQ:CMMB)

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

CMMB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CMMB Stock News Headlines

April 18, 2024 | globenewswire.com

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

April 8, 2024 | finance.yahoo.com

Chemomab Therapeutics Ltd. (CMMB)

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

April 2, 2024 | globenewswire.com

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

March 25, 2024 | globenewswire.com

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

March 7, 2024 | investorplace.com

CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023

March 7, 2024 | finanznachrichten.de

Chemomab Therapeutics Ltd: Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

March 7, 2024 | finance.yahoo.com

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 5, 2024 | prnewswire.com

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

February 20, 2024 | msn.com

Biotech Shares Massively Bid Up Before Opening Bell

February 20, 2024 | finance.yahoo.com

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

February 20, 2024 | prnewswire.com

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

February 14, 2024 | finance.yahoo.com

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

February 14, 2024 | prnewswire.com

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

February 5, 2024 | finance.yahoo.com

Chemomab Therapeutics to Participate in Upcoming Investor Conferences

January 30, 2024 | finance.yahoo.com

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

January 6, 2024 | benzinga.com

Chemomab Therapeutics Stock (NASDAQ:CMMB) Dividends: History, Yield and Dates

January 3, 2024 | finance.yahoo.com

Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024

December 29, 2023 | benzinga.com

Chemomab Therapeutics Stock (NASDAQ:CMMB) Insider Trades

December 21, 2023 | benzinga.com

Chemomab Therapeutics Stock (NASDAQ:CMMB), Analyst Ratings, Price Targets, Predictions

December 6, 2023 | msn.com

Here's Why Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Is a Great 'Buy the Bottom' Stock Now

November 16, 2023 | finance.yahoo.com

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

November 15, 2023 | markets.businessinsider.com

US Stocks Gain; Producer Prices Fall In October

November 15, 2023 | markets.businessinsider.com

Chemomab Reports Fast Track Designation For CM-101 - Quick Facts

November 15, 2023 | msn.com

Why is Liver Disease Focused Chemomab Stock Trading Higher Today?

November 15, 2023 | finance.yahoo.com

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

See More Headlines

Receive CMMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CMMB
CUSIP: N/A
CIK: 1534248
Web: www.chemomab.com
Phone: 972-77-331-0156
Fax: N/A
Employees: 20
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.00
High Stock Price Target: $7.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +929.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.12)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-24,220,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -114.00%
Return on Assets: -88.53%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.32
Quick Ratio: 4.32

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.54 per share
Price / Book: 0.44

Miscellaneous

Outstanding Shares: 11,050,000
Free Float: 9,734,000
Market Cap: $7.51 million
Optionable: Not Optionable
Beta: 0.36

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Adi Mor George Ph.D. (Age 42)
Co-Founder, Chief Scientific Officer, CEO & Executive Director
Comp: $435.4k
Ms. Sigal Fattal CPA (Age 53)
M.B.A., Chief Financial Officer
Comp: $258k
Barbara Lindheim
Consulting Vice President of Investor & Public Relations, Strategic Communications
Dr. Matthew B. Frankel M.B.A. (Age 54)
M.D., Chief Medical Officer & VP of Drug Development

Key Competitors

View All Competitors

CMMB Stock Analysis - Frequently Asked Questions

Should I buy or sell Chemomab Therapeutics stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chemomab Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CMMB shares.
View CMMB analyst ratings or view top-rated stocks.
What is Chemomab Therapeutics' stock price target for 2024?: 3 analysts have issued 1-year price targets for Chemomab Therapeutics' stock. Their CMMB share price targets range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 929.4% from the stock's current price.
View analysts price targets for CMMB or view top-rated stocks among Wall Street analysts.
How have CMMB shares performed in 2024?: Chemomab Therapeutics' stock was trading at $0.51 at the start of the year. Since then, CMMB stock has increased by 33.3% and is now trading at $0.68.
View the best growth stocks for 2024 here.
Are investors shorting Chemomab Therapeutics?: Chemomab Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 221,900 shares, an increase of 14.3% from the March 15th total of 194,200 shares. Based on an average trading volume of 224,000 shares, the short-interest ratio is presently 1.0 days. Currently, 1.9% of the shares of the stock are sold short.
View Chemomab Therapeutics' Short Interest.

When is Chemomab Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CMMB earnings forecast.
How were Chemomab Therapeutics' earnings last quarter?: Chemomab Therapeutics Ltd. (NASDAQ:CMMB) announced its quarterly earnings results on Thursday, March, 7th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.14. During the same period last year, the firm posted ($0.72) earnings per share.
How do I buy shares of Chemomab Therapeutics?: Shares of CMMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CMMB) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial